Loading data
CHRSNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of revenue | 13.81 m USD | 8.73 m USD | 158.99 m USD | 70.08 m USD | 57.59 m USD |
| Research and development expense | 108.89 m USD | 91.83 m USD | 109.44 m USD | 199.36 m USD | 363.11 m USD |
| Selling, general and administrative expense | 100.6 m USD | 125.48 m USD | 192.02 m USD | 198.48 m USD | 169.71 m USD |
| Operating profit | -181.13 m USD | -199.65 m USD | -203.2 m USD | -256.88 m USD | -263.86 m USD |
| Interest expense | 9 m USD | 10.73 m USD | 40.54 m USD | 32.47 m USD | 22.96 m USD |
| Profit before tax | -183.12 m USD | -215.39 m USD | -238.27 m USD | -291.75 m USD | -287.1 m USD |
| Income tax expense | — | — | -380 k USD | — | — |
| Net income (reported basis) | 168.02 m USD | 28.51 m USD | -237.89 m USD | -291.75 m USD | -287.1 m USD |
| Basic earnings per share | 1.43 USD/share | 0.25 USD/share | -2.53 USD/share | -3.76 USD/share | -3.81 USD/share |
| Diluted earnings per share | 1.43 USD/share | 0.25 USD/share | -2.53 USD/share | -3.76 USD/share | -3.81 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.